Sign in Subscribe

msi-h

A collection of 52 issues

Review examines immune checkpoint inhibitors in dMMR-MSI-H CRC

Skip to content The CRC Digest Review examines immune checkpoint inhibitors in dMMR-MSI-H CRC Comprehensive review discusses the immunological basis for exceptional responsiveness to PD-1 and CTLA-4 inhibitors in dMMR-MSI-H colorectal cancer, along with emerging resistance mechanisms and predictive biomarkers. (Front Immunol) This content is informational only and does not

This Week in CRC Research — July 12, 2026

Weekly colorectal cancer research intelligence

CRC Research Update — July 11, 2026

Today's colorectal cancer research highlights

RAS and BRAF status in MSI-H/dMMR metastatic CRC

Skip to content The CRC Digest RAS and BRAF status in MSI-H/dMMR metastatic CRC New guidance on the role of RAS and BRAF mutations in MSI-high and dMMR metastatic colorectal cancer. (Oncodaily) This content is informational only and does not constitute medical advice. Always consult your oncologist or care

CRC Research Update — July 10, 2026

Today's colorectal cancer research highlights

Stage III/IV MSI-H CRC Shows Reduced T-Cell Infiltration and Elevated IDO1

Skip to content The CRC Digest Stage III/IV MSI-H CRC Shows Reduced T-Cell Infiltration and Elevated IDO1 Analysis of 217 patients with dMMR/MSI-H colorectal cancer found that stage III/IV tumors had reduced immune infiltration and upregulated epithelial IDO1 expression compared to stage I/II, suggesting immune evasion

Sotorasib Plus Panitumumab Produces Response in Rare NRAS G12C-Mutated MSI-H Rectal Cancer

Skip to content The CRC Digest Sotorasib Plus Panitumumab Produces Response in Rare NRAS G12C-Mutated MSI-H Rectal Cancer A case report describes an objective tumor response to the KRAS G12C inhibitor sotorasib combined with EGFR blockade in a patient with advanced NRAS G12C-mutated, mismatch repair-deficient rectal adenocarcinoma refractory to immunotherapy.

CRC Research Update — July 08, 2026

Today's colorectal cancer research highlights

Microbiota influences immunotherapy efficacy in MSI-H colorectal cancer

Skip to content The CRC Digest Microbiota influences immunotherapy efficacy in MSI-H colorectal cancer Immune checkpoint inhibitors benefit patients with mismatch repair-deficient/microsatellite instability-high colorectal cancer, and gut microbiota appears to play a key role in treatment response. (Life Sciences) This content is informational only and does not constitute medical

CRC Research Finding

Skip to content The CRC Digest ◇ Review highlights gut microbiota's role in immunotherapy response, especially for MSI-H tumors A comprehensive review evaluates how gut microbiota and microbial metabolites influence colorectal cancer development, the tumor microenvironment, and immunotherapy responses, with emphasis on strategies for proficient mismatch repair/microsatellite-stable tumors